Leveraging Next-Generation Protein Sequencing™ in the CRO Setting with Platinum®

“Biomarker identification is a core offering, and we plan to utilize the technology to ensure batch-to-batch consistency of recombinant antibodies for our biopharmaceutical clients. We will also be providing assessments of in vivo stability for recombinant antibodies. This area is often overlooked; when people think of stability, they typically focus on shelf stability. However, post-translational modifications and in vivo stability are crucial, especially when dealing with bi-specific antibodies and antibody-drug conjugates.”

Explore this case study to learn how researchers at Gipfel are using Platinum® to enhance their capabilities in a wide range of applications like Identifying novel biomarkers, uncovering deeper insights into non-druggable disease pathways and phenotyping neglected diseases.